Home › Research › Treatments
Efficacy and Safety of an Herbal Therapy in Patients with Amnestic Mild Cognitive Impairment: A 24-Week Randomized Phase III Trial
Tian J, Shi J, Li T, Li L, Wang Z, Li X, Lv Z, Zheng Q et al.. Evidence-based complementary and alternative medicine : eCAM, 2017-05-17
Topic: Risk, prevention and care in population studies
Plain-language summary
Objective In the 24-week randomized, double-blind, double-placebo, parallel-controlled trial, we aimed to test the effects of herbal therapy with amnestic mild cognitive impairment (aMCI). Methods A total of 324 patients with aMCI entered a 2-week placebo run-in period followed by 24 weeks' treatment of either (a) herbal capsule (5 shenwu capsules/administration, 3 times/day) and placebo identical to donepezil tablets ( n = 216) or (b) donepezil (5 mg/day) and placebo identical to herbal capsule ( n = 108). Results Herbal therapy showed a significant improvement on the primary efficacy measure, measured by Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog), and showed a mean decrease from baseline of 4.23 points at the endpoint, without a significant difference from the donepezil group. Secondary efficacy measurement of the Logical Memory II Delayed Story Recall subtest (DSR) showed modest improvement in those taking herbal capsule compared to baseline, and there was no significant difference from donepezil group. The frequency of adverse events was much less in the herbal therapy group than the donepezil. Conclusion Herbal therapy demonstrated a significant improvement in cognition and memory, which were similar to the donepezil in patients with aMCI. Herbal therapy was safe and well tolerated. Trial registration This study is registered with clinicaltrials.gov NCT01451749.
What this study adds
Evidence grade: High
The record lists 216 participants. In this 24-week trial of 324 people with amnestic mild cognitive impairment, an herbal therapy improved cognition on the primary measure by about 4.23 points and was similar to donepezil, with fewer adverse events. Its stated limit: Showing ‘no significant difference’ from donepezil is not the same as proving equivalence; this excerpt doesn't state whether the trial was specifically designed and powered to test for non-inferiority, which is a different and more rigorous statistical standard.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Tian, J., Shi, J., Li, T., Li, L., Wang, Z., Li, X., et al. (2017). Efficacy and Safety of an Herbal Therapy in Patients with Amnestic Mild Cognitive Impairment: A 24-Week Randomized Phase III Trial. Evidence-based complementary and alternative medicine : eCAM. https://doi.org/10.1155/2017/4251747
Vancouver
Tian J, Shi J, Li T, Li L, Wang Z, Li X, et al. Efficacy and Safety of an Herbal Therapy in Patients with Amnestic Mild Cognitive Impairment: A 24-Week Randomized Phase III Trial. Evidence-based complementary and alternative medicine : eCAM. 2017. doi:10.1155/2017/4251747. PMID: 28596794.
BibTeX
@article{tian2017-28596794,
author = {Tian, J. and Shi, J. and Li, T. and Li, L. and Wang, Z. and Li, X. and Lv, Z. and Zheng, Q. and others},
title = {{Efficacy and Safety of an Herbal Therapy in Patients with Amnestic Mild Cognitive Impairment: A 24-Week Randomized Phase III Trial}},
journal = {Evidence-based complementary and alternative medicine : eCAM},
year = {2017},
doi = {10.1155/2017/4251747},
pmid = {28596794},
url = {https://doi.org/10.1155/2017/4251747}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Herbal therapy showed a significant improvement on the primary efficacy measure, measured by Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog), and showed a mean decrease from baseline of 4.23 points at the endpoint, without a significant difference from the donepezil group.
- Secondary efficacy measurement of the Logical Memory II Delayed Story Recall subtest (DSR) showed modest improvement in those taking herbal capsule compared to baseline, and there was no significant difference from donepezil group.
- Conclusion Herbal therapy demonstrated a significant improvement in cognition and memory, which were similar to the donepezil in patients with aMCI.
Why it matters
In this 24-week trial of 324 people with amnestic mild cognitive impairment, an herbal therapy improved cognition on the primary measure by about 4.23 points and was similar to donepezil, with fewer adverse events. The authors conclude the herbal therapy was safe and well tolerated, though the trial compared it only to donepezil, not to placebo.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants216
- Evidence strengthHigh
Limitations
Showing ‘no significant difference’ from donepezil is not the same as proving equivalence; this excerpt doesn't state whether the trial was specifically designed and powered to test for non-inferiority, which is a different and more rigorous statistical standard.
How this study scored 46/100
Published in a peer-reviewed journal. Scored zero for study design and effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Evidence-based complementary and alternative medicine : eCAM) |
| Journal's citation record | 2 / 4 | Evidence-based Complementary and Alternative Medicine: journal h-index 167 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2017 — within 10 year(s) of the newest study here |
| Sample size | 2 / 4 | 216 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 2 / 7 | Cited 12 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.1 citations a year over 11 year(s) since 2017 |
| Impact for its field and year | 2 / 6 | Cited 1.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 5 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Yongyan Wang: h-index 28 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Capital Medical University: institution h-index 643 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 28596794) |
| Free to read | 2 / 2 | Free to read |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1155/2017/4251747
- PubMed: 28596794
- Original source →
- Free full text: Evidence-based Complementary and Alternative Medicine →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.